| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17476348.2016.1258306 |
| P698 | PubMed publication ID | 27817219 |
| P50 | author | Kevin A Cook | Q61439548 |
| P2093 | author name string | Donald D Stevenson | |
| P2860 | cites work | Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force | Q22305330 |
| Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 | Q24290855 | ||
| Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 | ||
| Update on the Management of Aspirin-Exacerbated Respiratory Disease | Q26749097 | ||
| Platelets in patients with aspirin-exacerbated respiratory disease | Q28080840 | ||
| Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q28138991 | ||
| The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance | Q28162610 | ||
| Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma | Q28165524 | ||
| Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups | Q28174568 | ||
| Safety of a specific COX-2 inhibitor in aspirin-induced asthma | Q28177184 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma | Q28193250 | ||
| The safety of celecoxib in patients with aspirin-sensitive asthma | Q28193684 | ||
| The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions | Q28193909 | ||
| The natural history and clinical characteristics of aspirin-exacerbated respiratory disease | Q28194291 | ||
| Natural history and clinical features of aspirin-exacerbated respiratory disease | Q28195561 | ||
| Aspirin desensitization in patients with AERD | Q28195567 | ||
| A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge | Q28195706 | ||
| Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib | Q28195999 | ||
| Aspirin and NSAID sensitivity | Q28199084 | ||
| Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease | Q28200319 | ||
| Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study | Q28200601 | ||
| Selection of patients for aspirin desensitization treatment | Q28200629 | ||
| Effect of leukotriene modifier drugs on the safety of oral aspirin challenges | Q28212449 | ||
| Medical and surgical considerations in patients with Samter's triad | Q28213207 | ||
| Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease | Q28213966 | ||
| Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting | Q28217466 | ||
| Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper | Q28219101 | ||
| The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges | Q28222887 | ||
| Cysteinyl leukotrienes and their receptors; emerging concepts | Q28243252 | ||
| Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs | Q28300126 | ||
| Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association | Q29620546 | ||
| Aspirin-exacerbated respiratory disease: evaluation and management | Q30477625 | ||
| Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease | Q33598927 | ||
| Aspirin-exacerbated respiratory disease: not always "adult-onset" | Q33772263 | ||
| Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma | Q33905623 | ||
| Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma | Q33921113 | ||
| Intolerance to aspirin. Clinical studies and consideration of its pathogenesis | Q34236999 | ||
| American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee | Q34273218 | ||
| Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. | Q34295682 | ||
| An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. | Q34389485 | ||
| Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
| 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Q34500921 | ||
| The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes | Q35190760 | ||
| Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation | Q35545787 | ||
| Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation | Q35663953 | ||
| 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis | Q36870924 | ||
| Aspirin sensitivity and desensitization for asthma and sinusitis | Q37390928 | ||
| Pharmacotherapy of tension-type headache (TTH). | Q37492582 | ||
| EFNS guideline on the treatment of tension-type headache - report of an EFNS task force | Q37756222 | ||
| Role of aspirin desensitization in the management of chronic rhinosinusitis | Q37849552 | ||
| Evidence for efficacy of acute treatment of episodic tension-type headache: methodological critique of randomised trials for oral treatments | Q38241482 | ||
| Aspirin-exacerbated respiratory disease: characteristics and management strategies | Q38455960 | ||
| Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma | Q38668673 | ||
| Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery | Q40199713 | ||
| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial | Q40445632 | ||
| Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial | Q40693199 | ||
| 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoraci | Q41025999 | ||
| Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs | Q41148151 | ||
| Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease | Q42950579 | ||
| Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience | Q43433421 | ||
| Use of nasal inspiratory flow rates in the measurement of aspirin-induced respiratory reactions. | Q43976747 | ||
| 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q44265041 | ||
| Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis | Q44432091 | ||
| Platelets are essential for leukocyte recruitment in allergic inflammation. | Q44504339 | ||
| Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes | Q44904189 | ||
| The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease | Q45390313 | ||
| Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease | Q46214374 | ||
| Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily | Q46432280 | ||
| Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation | Q46711899 | ||
| Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease | Q48041264 | ||
| European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted | Q48527068 | ||
| Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 | ||
| Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma | Q49152600 | ||
| An Hourly Dose-Escalation Desensitization Protocol for Aspirin-Exacerbated Respiratory Disease. | Q51603354 | ||
| Omalizumab in the treatment of aspirin-exacerbated respiratory disease. | Q51661831 | ||
| Aspirin exacerbated respiratory disease: the search for a biomarker. | Q51680404 | ||
| Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. | Q52469277 | ||
| Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. | Q53873040 | ||
| 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q56674421 | ||
| AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update | Q57072671 | ||
| P433 | issue | 12 | |
| P921 | main subject | aspirin | Q18216 |
| P304 | page(s) | 1305-1316 | |
| P577 | publication date | 2016-11-06 | |
| P1433 | published in | Expert Review of Respiratory Medicine | Q15754583 |
| P1476 | title | Current complications and treatment of aspirin-exacerbated respiratory disease | |
| P478 | volume | 10 |
| Q38741861 | Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism | cites work | P2860 |
Search more.